A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy

Cancer Cell International

Volumn 10, Issue , 2010, Pages

  Cheung, Chun Hei Antonio ^a,d   Sun, Xueying ^a,b   Kanwar, Jagat R ^a,e,f   Bai, Ji Zhong ^a   Cheng, LiTing ^c   Krissansen, Geoffrey W ^a  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e DEAKIN UNIVERSITY   (Australia)

^f Technology Precinct (GTP)   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; POLYARGININE; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA;

AFFINITY CHROMATOGRAPHY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; DRUG ANTAGONISM; ENZYME ACTIVATION; FAR WESTERN BLOTTING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN EXPRESSION; UTERINE CERVIX CANCER;

EID: 77957194642     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-10-36     Document Type: Article

References (37)

1. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002, 5:65-72. 10.1016/S1368-7646(02)00049-3, 12135582.
2. Cheung CH, Chen HH, Kuo CC, Chang CY, Coumar MS, Hsieh HP, Chang JY. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer 2009, 8:43. 10.1186/1476-4598-8-43, 2714493, 19575780.
3. Moriai R, Tsuji N, Moriai M, Kobayashi D, Watanabe N. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 2009, 117:261-271. 10.1007/s10549-008-0164-5, 18815881.
4. Jiang G, Ren B, Xu L, Song S, Zhu C, Ye F. Survivin may enhance DNA double-strand break repair capability by up-regulating Ku70 in human KB cells. Anticancer Res 2009, 29:223-228.
5. Nakamura M, Tsuji N, Asanuma K, Kobayashi D, Yagihashi A, Hirata K, Torigoe T, Sato N, Watanabe N. Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric cancer patients. Cancer Sci 2004, 95:44-51. 10.1111/j.1349-7006.2004.tb03169.x, 14720326.
6. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005, 65:4881-4887. 10.1158/0008-5472.CAN-04-3028, 15930309.
7. Seo SI, Gera L, Zhau HE, Qian WP, Iqbal S, Johnson NA, Zhang S, Zayzafoon M, Stewart J, Wang R, et al. BKM1740, an acyl-tyrosine bisphosphonate amide derivative, inhibits the bone metastatic growth of human prostate cancer cells by inducing apoptosis. Clin Cancer Res 2008, 14:6198-6206. 10.1158/1078-0432.CCR-08-1023, 18829499.
8. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001, 40:1117-1123. 10.1021/bi001603q, 11170436.
9. Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, Baratti D, et al. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol 2007, 29:453-466.
10. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998, 58:5315-5320.
11. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004, 114:1117-1127. 522254, 15489959.
12. Croci DO, Cogno IS, Vittar NB, Salvatierra E, Trajtenberg F, Podhajcer OL, Osinaga E, Rabinovich GA, Rivarola VA. Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem 2008, 105:381-390. 10.1002/jcb.21836, 18553460.
13. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009, 15:3872-3880. 10.1158/1078-0432.CCR-08-1946, 19470738.
14. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A, Shamsili S. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009, 27:4481-4486. 10.1200/JCO.2008.21.1862, 19687333.
15. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008, 26:5198-5203. 10.1200/JCO.2008.17.2064, 18824702.
16. Hansen JB, Fisker N, Westergaard M, Kjaerulff LS, Hansen HF, Thrue CA, Rosenbohm C, Wissenbach M, Orum H, Koch T. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther 2008, 7:2736-2745. 10.1158/1535-7163.MCT-08-0161, 18790754.
17. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, Kita A, Tominaga F, Yamanaka K, Kudoh M, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007, 67:8014-8021. 10.1158/0008-5472.CAN-07-1343, 17804712.
18. Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O, Margolis RL. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Molecular Cell 2000, 6:183-189. 10.1016/S1097-2765(00)00019-8, 10949039.
19. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nature Struct Biol 2000, 7:602-608. 10.1038/77929, 10876248.
20. Muchmore SW, Chen J, Jakob C, Zakula D, Matayoshi ED, Wu W, Zhang H, Li F, Ng SC, Altieri DC. Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Molecular Cell 2000, 6:173-182. 10.1016/S1097-2765(00)00018-6, 10949038.
21. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584. 10.1038/25141, 9859993.
22. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001, 93:1541-1552. 10.1093/jnci/93.20.1541, 11604477.
23. Wu J, Apontes P, Song L, Liang P, Yang L, Li F. Molecular mechanism of upregulation of survivin transcription by the AT-rich DNA-binding ligand, Hoechst33342: evidence for survivin involvement in drug resistance. Nucleic Acids Res 2007, 35:2390-2402. 10.1093/nar/gkm149, 1874665, 17392340.
24. Shen C, Liu W, Buck AK, Reske SN. Pro-apoptosis and anti-proliferation effects of a recombinant dominant-negative survivin-T34A in human cancer cells. Anticancer Res 2009, 29:1423-1428.
25. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001, 98:635-640. 10.1073/pnas.230450097, 14640, 11149963.
26. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000, 97:13103-13107. 10.1073/pnas.240390697, 27185, 11069302.
27. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:13003-13008. 10.1073/pnas.97.24.13003, 27168, 11087855.
28. Cheung CHA, Kanwar J, Krissansen GW. A cell-permeable dominant-negative Survivin protein as a tool to understand how Survivin maintains tumour cell survival. EJC Suppl 2006, 4:488.
29. Xu JH, Wang AX, Huang HZ, Wang JG, Pan CB, Zhang B. Survivin shRNA induces caspase-3-dependent apoptosis and enhances cisplatin sensitivity in squamous cell carcinoma of the tongue. Oncol Res 2010, 18:377-385. 10.3727/096504010X12644422320663, 20441052.
30. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000, 60:2805-2809.
31. Taghiyev AF, Guseva NV, Sturm MT, Rokhlin OW, Cohen MB. Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment. Cancer Biol Ther 2005, 4:382-390. 10.4161/cbt.4.4.1615, 15846101.
32. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008, 133:693-703. 10.1016/j.cell.2008.03.036, 18485876.
33. Chen Y, Li W, Zhou JH, Li DM, Xia XM, Huang LN, Li BQ. Molecular mechanism of anti-apoptotic action of survivin in NCI-H446 lung cancer cells. Zhonghua Zhong Liu Za Zhi 2006, 28:413-417.
34. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009, 28:461-468. 10.1038/onc.2008.394, 18978815.
35. Sainz RM, Reiter RJ, Tan DX, Roldan F, Natarajan M, Quiros I, Hevia D, Rodriguez C, Mayo JC. Critical role of glutathione in melatonin enhancement of tumor necrosis factor and ionizing radiation-induced apoptosis in prostate cancer cells in vitro. J Pineal Res 2008, 45:258-270. 10.1111/j.1600-079X.2008.00585.x, 18384530.
36. Fornaro M, Plescia J, Chheang S, Tallini G, Zhu YM, King M, Altieri DC, Languino LR. Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway. J Biol Chem 2003, 278:50402-50411. 10.1074/jbc.M307627200, 14523021.
37. Savulescu J. Harm, ethics committees and the gene therapy death. J Med Ethics 2001, 27:148-150. 10.1136/jme.27.3.148, 1733412, 11417019.